Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 1-A POS Offering statement (post-effective amendment)
- PART II AND III Amendment No. 6 to Post-qualification Offering Circular
- EX1A-4 SUBS AGMT Form of Subscription Agreement
- EX1A-6 MAT CTRCT Lease Agreement Dated April 18, 2019
- EX1A-6 MAT CTRCT Consulting Agreement Dated August 1, 2020 Between the Company and Mark Wegenka
- EX1A-11 CONSENT Consent of Deloitte & Touche LLP
- EX1A-12 OPN CNSL Opinion of Greenberg Traurig, P.a
Emerald Health Pharmaceuticals similar filings
Filing view
External links
Exhibit 11.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the use in this Post-Qualification Amendment #6 to the Offering Circular of our report dated April 28, 2020 relating to the financial statements of Emerald Health Pharmaceuticals Inc.
/s/ DELOITTE & TOUCHE LLP
San Diego, California
November 6, 2020